Outlook Therapeutics (OTLK) Amortization of Deferred Charges (2015 - 2022)

Outlook Therapeutics (OTLK) has 8 years of Amortization of Deferred Charges data on file, last reported at $2.5 million in Q4 2022.

• Amortization of Deferred Charges for Q4 2022 came in at $2.5 million, up 633.89% year-over-year; the trailing twelve-month figure through Sep 2023 was $2.5 million (up 52.83% YoY), and the FY2024 annual result was $2.7 million, up 6.01% from the prior year.
• Amortization of Deferred Charges grew to $2.5 million in Q4 2022 per OTLK's latest filing, from $455643.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $2.5 million in Q4 2022 and troughed at $15722.0 in Q4 2019.
• A 5-year average of $409182.7 and a median of $299193.5 in 2021 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2019 and 2020: Amortization of Deferred Charges tumbled 96.51% in 2019, then jumped 849.05% in 2020.
• A 5-year view of Amortization of Deferred Charges shows it stood at $450381.0 in 2018, then plunged by 96.51% to $15722.0 in 2019, then jumped by 849.05% to $149210.0 in 2020, then surged by 131.03% to $344716.0 in 2021, then jumped by 633.89% to $2.5 million in 2022.
• Business Quant data shows OTLK's Amortization of Deferred Charges at $2.5 million in Q4 2022, $455643.0 in Q3 2022, and $436593.0 in Q2 2022.